Immuneering Corp (IMRX) Expected Move

Tracking the IMRX expected move helps you see how far Immuneering Corp's options market is pricing the stock to travel over a given period — whether that's the next day, week, or earnings cycle. Immuneering Corp's expected move is derived directly from option premiums and gives you an objective range to plan trades, set strikes, and manage risk. Use our scanner to monitor the IMRX expected move for this week's options, in real time.

The expected move is typically calculated from at-the-money straddle prices (or a blend of straddles and strangles) and represents roughly a one-standard-deviation range over the chosen timeframe. For IMRX, comparing the implied expected move to actual realized moves over similar windows tells you whether the options market has historically overestimated or underestimated volatility. The IMRX expected move for this week's options pricing is especially useful for short-dated traders, earnings players, and anyone selling premium who needs to know where the market thinks Immuneering Corp is unlikely to go.

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.

Iron condors, weekly premium sales, directional swing trades — they all live or die by where the market thinks the stock won't go. Our scanner tracks the IMRX expected move across every expiration, benchmarks it against realized moves, and shows you when implied ranges are out of line with history. The Immuneering Corp expected move for this week's options is the fastest read on short-term risk, which gives you a quick way to interpret what the options market thinks about IMRX.